Ultragenyx is laying off about 20% of its staff and ending development of two rare disease drugs, according to the company announcement summarized by STAT. The move follows another failed study.
The available report does not identify the drugs or provide further details about the study results or the timing of the job cuts.
Sources: STAT News.